Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2026.
“ORIC Pharmaceuticals, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.”
Oric Pharmaceuticals, Inc. — fact timeline
Source-grounded facts extracted from Oric Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Oric Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.9 million affecting discovery research group (approximately 20% workforce reduction).
“On August 12, 2025, the Company initiated a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits.”
Oric Pharmaceuticals, Inc. reported financial results for for the quarter ended March 31, 2024.
“ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.